Fluorine-containing molecules have found applications in the pharmaceutical and agrochemical sector because of the thermodynamic and kinetic stability of C--F σ-bonds,^[@ref1]^ a property offering protection against enzymatic metabolism.^[@ref1]^ Today, pharmacophores often bear a trifluoromethyl or difluoromethyl motif in an aromatic system, thereby increasing the demand for methods to install or interchange these groups in a late-stage fashion.^[@ref2]^ In this context, molecular editing enabling precision hydrodefluorination (HDF) of trifluoromethylarenes into difluoromethylarenes for applications in drug discovery remains a highly challenging endeavor because the bond dissociation energy (BDE) of C--F bonds decreases as fluorine substitution takes place ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}A).^[@ref3],[@cit4a]^ Pioneering studies have reported strategies employing boron, silylium or phosphine adducts,^[@ref5]^ and (transition) metals, but uncontrolled defluorination could not be avoided for many of these processes.^[@ref6]^ Jui and co-workers demonstrated that hydrofluorination is accomplished with cesium formate and the Miyake phenoxazine photocatalyst under blue light activation ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}B).^[@cit7a]^ This protocol is applicable to unactivated trifluoromethylarenes adorned with electron-donating groups. Despite these significant advances in the field, HDF of highly activated trifluoromethylarenes featuring electron-withdrawing groups to access difluoromethylarenes has not been accomplished. This is unexpected because most tri- and difluoromethylated drugs feature the CF~3~ or CF~2~H group on electron-poor arenes due to their higher resistance to oxidation and defluorination in comparison with electron-rich counterparts.^[@ref8]^

![Hydrodefluorination of Trifluoromethylarenes in Drug Discovery](ja0c03881_0001){#sch1}

Mechanistic studies reported in 1997 by Savéant and Thiébault provided useful information on the electrochemical reductive cleavage of C--F bonds for 4-cyanofluorotoluenes **1a**--**c** and trifluoromethylbenzene.^[@cit4a]^ The process involves fluoride expulsion from a radical anion, followed by reduction of the resulting neutral radical, and protonation. As expected, the standard reduction potential for the formation of the radical anion decreases from **1a** to **1c**, although these are closely spaced (narrow redox window), while the instability of the radical anion toward fluoride mesolytic cleavage increases. Facile exhaustive defluorination is observed experimentally, the challenge at hand for these highly activated substrates ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}).

![Electrochemical Reductive Cleavage of Trifluoromethylarenes: Standard Reduction Potentials (V vs Standard Calomel Electrode (SCE) in DMF) and Cleavage Rate Constants\
*E*~1/2~ (V vs SCE in DMF).^[@cit4b]^](ja0c03881_0002){#sch2}

Preliminary experiments with 4-(trifluoromethyl)benzonitrile **1a** showed that no product **1b** was formed applying the protocols of Prakash or Lalic ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 1 and 2).^[@ref6]^ Moreover, the conditions applied for known photoredox defluorination using trifluoromethylarenes led mainly to recovery of starting material ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 3--5).^[@cit7a]−[@cit7c]^ The more electrophilic nature of the difluorinated benzylic radical derived from electron-deficient **1a** compared to electron-rich substrates encouraged a study examining hydrogen atom donors (HAD) other than cesium formate.^[@cit7a]^ Gratifyingly, the reaction of **1a** in the presence of 2.5 mol % *fac*-Ir(ppy)~3~, 4-hydroxythiophenol (4-HTP) and a combination of 2,2,6,6-tetramethylpiperidine (TMP) and 1,2,2,6,6-pentamethylpiperidine (PMP) in 1,2-dichloroethane (DCE) under visible light activation (blue LED) gave **1b** in 53% with 5:1 selectivity (**1b**:**1c**). The fully reduced 4-methylbenzonitrile product was not detected ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 6). Organophotocatalyst 2,4,5,6-tetrakis(diphenylamino)isophthalonitrile (4-DPA-IPN, 2.5 mol %) was a suitable metal-free replacement for *fac*-Ir(ppy)~3~ affording **1b** in 62% yield with similar selectivity ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 7). Lowering catalyst loading did not affect the reaction outcome (65% yield, **1b**:**1c** = 5:1) ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 8). Hydrogen atom donors including thiols other than 4-HTP, 1,4-cyclohexadiene, the Hantzsch ester, (Me~3~Si)~3~SiH, or CsOCOH were less or not suitable under otherwise similar reaction conditions ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 9--17). The photocatalyst, HAD, base, and blue light are essential components for this transformation to proceed ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 18--23).

###### Experiments for the Hydrodefluorination of 4-(Trifluoromethyl)benzonitrile **1a**

![](ja0c03881_0007){#GRAPHIC-d7e506-autogenerated}

  Entry                               Alterations to conditions                                                                                                           Yield[a](#t1fn1){ref-type="table-fn"}(ratio **1b**:**1c**)
  ----------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------
  1                                   Mg^0^ (30 equiv), H~2~O/AcOH/DMSO                                                                                                   0%
  2                                   Pd(OAc)~2~ (3 mol %), CuF~2~ (20 mol %), 2-pyridone (5 mol %), KOSiMe~3~ (7.0 equiv), DMF, 45 °C, *then t*BuOH (2.0 equiv), 60 °C   0%
  3[b](#t1fn2){ref-type="table-fn"}   Miyake Phenoxazine (2 mol %), II (3 equiv), blue LED, DMSO, 50 °C, 24 h                                                             4% (2:1)
  4[c](#t1fn3){ref-type="table-fn"}   *fac*-Ir(ppy)~3~ (1.0 mol %), TMP (2.0 equiv), HBPin (3.0 equiv), blue LED, DCE, rt, 24 h                                           0%
  5[d](#t1fn4){ref-type="table-fn"}   PTH (10 mol %), VI (10 mol %), II (3 equiv), blue LED, 5% H~2~O/DMSO, rt, 24 h                                                      0%
  6                                   *fac*-Ir(ppy)~3~ (2.5 mol %)                                                                                                        53% (5:1)
  7                                   4-DPA-IPN (2.5 mol %)                                                                                                               62% (5:1)
  8                                   No alteration                                                                                                                       65% (5:1)
  9                                   I (6 equiv) instead of III                                                                                                          trace
  10                                  II (6 equiv) instead of III                                                                                                         trace
  11                                  IV (6 equiv) instead of III                                                                                                         0%
  12                                  V (6 equiv) instead of III                                                                                                          15% (5:1)
  13                                  VI (6 equiv) instead of III                                                                                                         4% (8:1)
  14                                  VII (6 equiv) instead of III                                                                                                        4% (8:1)
  15                                  VIII (6 equiv) instead of III                                                                                                       5% (8:1)
  16                                  IX (6 equiv) instead of III                                                                                                         22% (7:1)
  17                                  X (6 equiv) instead of III                                                                                                          22% (7:1)
  18                                  no PMP                                                                                                                              51% (5:1)
  19                                  no TMP                                                                                                                              31% (\>20:1)
  20                                  no TMP and no PMP                                                                                                                   0%
  21                                  no light                                                                                                                            0%
  22                                  no 4-HTP                                                                                                                            0%
  23                                  no photocatalyst                                                                                                                    0%

Combined yields of **1b** and **1c** determined by ^19^F NMR using 4-fluoroanisole as internal standard; the ratio of **1b**:**1c** is given in parentheses.

Reaction carried out on **14a**.

Conditions of ref ([@cit7c]) with no alkene.

Conditions of ref ([@cit7b]) with no alkene. PTH = 10-phenyl-10*H*-phenothiazine. BDE values for arylthiols from ref ([@ref9]).

With the optimal reaction conditions in hand, we explored the generality of this HDF reaction ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}). 2-(Trifluoromethyl)benzonitrile gave **2b** in 63% yield and \>20:1 selectivity favoring CF~2~H. Additional functionalities on the aromatic ring including fluorine, methoxy, or acetamide were tolerated (**3b**, **5b**, and **7b**, 42--88%) with high selectivity for CF~2~H (\>10:1). Methyl and ethyl 4-(trifluoromethyl)benzoate **4a** and **8a** with a carboxylic ester instead of a cyano group were transformed into difluoromethylated analogues **4b** and **8b** in moderate yields (30% and 40%) and 3:1 selectivity. When the catalyst loading was increased to 2.5 mol %, the yield was improved (**8b**, 63%), but the product resulting from double reductive defluorination was formed preferentially (**8b**:**8c** = 1:2). Unprotected sulfonamide **6b** was within reach with excellent selectivity.

![Scope of HDF\
Yields and CF~2~H/CH~2~F ratio determined by quantitative ^19^F NMR spectroscopy using 4-fluoroanisole as internal standard. Yields of isolated products (RCF~2~H only) are given in parentheses.\
2.5 mol % 4-DPA-IPN.\
Solvent is DCE/DMSO (19:1, v/v, *c* = 0.025 M).](ja0c03881_0003){#sch3}

Complex molecules of biological relevance were examined next. Bicalutamide, a drug used to treat prostate cancer, underwent reductive defluorination affording **9b** isolated in 43% yield and 10:1 CF~2~H/CH~2~F selectivity.^[@ref10]^ The doubly trifluoromethylated cannabinoid receptor agonist BAY 59-3074 **10a** reacted exclusively at the arene. An analogue of Enobosarm featuring three trifluoromethylaryl groups served the purpose to investigate a more complex case of "arene versus arene" chemoselectivity.^[@ref11]^ Hydrodefluorination occurred with excellent CF~2~H/CH~2~F selectivity (\>20:1) at a single site, leaving the 3,5-bis-trifluoromethylarene motif untouched (**11b**, 53%); this result corroborates a control experiment that demonstrated that 3,5-bis-trifluoromethylbenzene was unreactive under our reaction conditions. Bendroflumethiazide **12a**, a drug used for mild heart failure and hypertension via vasodilation,^[@ref12]^ was also subjected to C--F bond reduction. Our protocol, slightly modified in order to solubilize the starting material (solvent mixture of DCE/DMSO), gave CF~2~H-bendroflumethiazide **12b** in 56% yield although with decreased selectivity (CF~2~H/CH~2~F ratio = 4:1). This result is significant because sulfonamides and/or amines can coordinate some metals, rendering late-stage cross-coupling strategies toward aryl--CF~2~H bond construction more challenging.^[@ref13]^ Enzalutamide, a hormonal therapy drug used to treat prostate cancer, also underwent HDF. This reaction yielded with excellent selectivity the difluoromethylated analogue **13b** isolated in 40% yield. The usefulness of this HDF protocol was further illustrated with the synthesis of **14b**, a molecule with strong androgen receptor binding affinity *in vivo*.^[@ref14]^ This biologically relevant compound was previously prepared in eight steps.^[@ref15]^ With our protocol, **14b** was obtained in two steps; the precursor **14a** was prepared in one step from commercially available materials,^[@ref16]^ and HDF gave **14b** isolated in 60% yield. Alternative photoredox HDF protocols were not effective.^[@ref17]^

Given the relevance of this novel HDF methodology for drug discovery, we conducted a robustness screening experiment to gain further information on its tolerance to various pharmacophores and functionalities ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}).^[@ref18]^ Common functional groups compatibility was investigated with para-substituted toluenes **A**, revealing tolerance to bromine, amine, alcohol, carboxylic acid, and aldehyde functionalities. Next, a range of 2-pyridines **B**, 5-pyrimidines **C**, 3-pyridazines **D**, and 2-pyrazines **E** were subjected to screening. While 2-pyridines and 5-pyrimidines were broadly tolerated, 3-pyridazines and 2-pyrazines more often prevented hydrodefluorination. Isoxazoles **G** and pyrazoles **H** with various substitution patterns were well accepted. In addition, fused heteroarenes such as pyrazolopyridines **F**, benzooxazoles **I**, benzothiazoles **J**, indazoles **K**, and benzimidazoles **L** did not hamper the HDF of **1a**, a benefit considering the frequency of these motifs in modern pharmaceutical drugs.^[@ref19]^ Many of the heterocycles investigated in this study could deactivate transition-metal catalysts by coordination,^[@ref20],[@ref21]^ and the HDF offers an alternative to these methods.

![Additive-Based Screening\
All reactions were performed on 2.5 μmol scale in a 96-well plate suited for photoredox chemistry. Crude mixtures were analyzed by GC-FID/MS.^[@ref16]^](ja0c03881_0004){#sch4}

Continuous-flow chemistry was considered to scale-up the HDF of **1a** ([Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}).^[@ref22]^ The first reactions were performed in a microflow system made of a perfluoroalkoxyalkane capillary (internal diameter = 0.5 mm; internal volume = 2.0 mL) on a scale similar to batch (0.2 mmol); **1b** was obtained in 69% yield with 5:1 selectivity (CF~2~H/CH~2~F), within a 15 min residence time (*t*~R~) at a flow rate of 0.133 μL/min. Additionally, **13b** (0.2 mmol) was isolated in 25% yield with 10:1 selectivity after a 7.5 min *t*~R~ at a flow rate of 0.266 μL/min. Starting with 2.5 g of **1a** (14.6 mmol), 1.4 g of **1b** (5:1) was produced in a 15 min *t*~R~ at a flow rate of 0.133 μL/min.

![Photoredox Hydrodefluorination under Continuous-Flow Conditions\
Yields of isolated products.](ja0c03881_0005){#sch5}

Various experiments were performed to gain preliminary insight on the mechanism of this transformation ([Scheme [6](#sch6){ref-type="scheme"}](#sch6){ref-type="scheme"}).

![(A) Mechanistic Experiments; (B) Stern--Volmer Luminescence Quenching Studies; (C) Proposed Reaction Mechanism\
Yields determined by quantitative ^19^F NMR using 4-fluoroanisole as internal standard.](ja0c03881_0006){#sch6}

A radical scavenger experiment performed with TEMPO led to the formation of adduct **15** ([Scheme [6](#sch6){ref-type="scheme"}](#sch6){ref-type="scheme"}A). When the reaction of **1a** was carried out in the presence of styrene and 4-HTP, **16** was obtained in 56% yield ([Scheme [6](#sch6){ref-type="scheme"}](#sch6){ref-type="scheme"}A). These data are consistent with the formation of a benzylic radical species formed by mesolytic C--F bond cleavage of a radical anion. Deuterium was incorporated in the product (40% yield, H/D ratio of 3:2) when *d*~2~-4-HTP was used instead of 4-HTP, indicating that 4-HTP is a plausible HAD in this reaction ([Scheme [6](#sch6){ref-type="scheme"}](#sch6){ref-type="scheme"}A). Stern--Volmer luminescence quenching experiments provided additional information ([Scheme [6](#sch6){ref-type="scheme"}](#sch6){ref-type="scheme"}B). We found that the combination of 4-HTP and TMP (1:1) quenches \*PC^*n*^; this is in contrast to TMP, PMP, CsOCOHor (TMS)~3~SiH. The inability of **1a** to quench the excited state of the photocatalyst \*PC^*n*^ advocates against an oxidative quenching cycle whereby the radical anion **17** would result from SET involving \*PC^*n*^/PC^*n*+1^(−1.28 V).^[@ref23]^ These preliminary findings led us to propose the reductive quenching cycle shown in [Scheme [6](#sch6){ref-type="scheme"}](#sch6){ref-type="scheme"}C as a plausible mechanistic pathway. Irradiation with light affords the excited state catalyst \*PC. Under basic conditions, deprotonation of 4-HTP leads to a thiolate **A** capable of reductive quenching of \*PC, a process yielding the corresponding thiyl radical **B**,^[@ref24]^ and the reduced photocatalyst (PC^*n*^/PC^*n*--1^= −1.52 V).^[@ref23]^ In this scenario, the substrate acts as the oxidant to return the photocatalyst to its native oxidation state with release of the  radical anion species that undergoes mesolytic cleavage of fluoride.^[@ref25]^ This latter process leads to the C-centered difluorobenzylic radical **18** which is trapped by 4-HTP affording **1b**.

In conclusion, the reductive defluorination of electron-poor trifluoromethylarenes is accomplished under basic conditions with 2,4,5,6-tetrakis(diphenylamino)isophthalonitrile as the organophotocatalyst,^[@ref26]^ 4-hydroxythiophenol as the HAD, and blue light. This operationally simple protocol tolerates a wide range of functional groups and heteroarenes frequently seen in medicinal chemistry programs, and allows the direct conversion of complex trifluoromethylated drugs into their difluoromethyl analogues. Mechanistic studies allude to a catalytic cycle whereby the photocatalyst is reduced by the HAD and returned in its native oxidation state by the trifluoromethylarene that acts as oxidant.

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/jacs.0c03881](https://pubs.acs.org/doi/10.1021/jacs.0c03881?goto=supporting-info).Additional optimization, mechanistic data, cyclic voltammetry, experimental procedures and analytical data (^1^H, ^19^F, ^13^C NMR, high resolution mass spectrometry) for all new compounds ([PDF](http://pubs.acs.org/doi/suppl/10.1021/jacs.0c03881/suppl_file/ja0c03881_si_001.pdf))
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